Introducing MacuMira

A non-invasive Microcurrent Stimulation for Dry AMD

The MacuMira device in partnership with Keeler empowers eyecare professionals with a safe, effective, and non-invasive treatment that delivers measurable vision improvements.

The MacuMira solution

AMD is the leading cause of blindness in adults, affecting over 1.5 million Australians¹ and tens of thousands of New Zealanders².

The MacuMira device is the first and only TGA and Medsafe-listed microcurrent treatment for Dry AMD.

Using non-invasive Microcurrent Stimulation, the device offers a breakthrough approach, designed to improve visual function and independence for patients.

Easy to administer, the device elevates patient care via a safe, and pain-free treatment that requires no injections or systemic drugs.

Visit MacuMira

 

¹ Australian Government Department of Health, National Strategic Action Plan for Macular Disease (2019) prevalence of all stages of AMD in adults over 50. ² bpacNZ, Macular degeneration: the importance of early detection (2015) – prevalence of all stages of AMD in adults aged 45–85.

How it works

  • •  A loading phase of 4 x 32-minute sessions improves vision within days.
  • •  One maintenance treatment every 2–3 months sustains results.
  • •  Microcurrent Stimulation (MCS) stimulates the mitochondria, which boosts ATP production for healthier retinal cells.
  • •  Most patients start to see improvements within 10 days*

 

*Parkinson, K. M., Sayre, E. C., & Tobe, S. W. (2023). Evaulation of visual acuity in dry AMD patients after microcurrent electrical stimulation.
Int. Journal of Retina and Vitreous, 9, 36.

MacuMira introduction for clinicians

ParagonCare is proud to introduce MacuMira, a groundbreaking, non-invasive treatment for Dry AMD.

Watch this video below to discover how MacuMira can elevate your patient care with innovative Dry AMD technology.

Discover MacuMira

 

Be one of the first to experience the Keeler/MacuMira device in person.

Book a Demo